Adolescent & Young Adult Lymphoma Program
A dedicated program for teens and young adults with lymphoma
Lymphoma is the most common type of cancer in adolescents and young adults. Yet physicians are still unsure about how to treat people with lymphoma between the ages of 18 and 30. Young patients also have other needs during this critical time in their lives — finishing their educations, living on their own for the first time, and feeling concerned about preserving their fertility.
To meet those needs, the pediatric lymphoma team at NewYork-Presbyterian Komansky Children's Hospital established a collaboration with NewYork-Presbyterian/Weill Cornell Medical Center's adult lymphoma program to form the Adolescent and Young Adult Lymphoma Program. Its goal: to ensure the most effective and appropriate medical care for each patient, meet their nonmedical needs, and ensure access to clinical trials of promising new therapies. Patients benefit from:
- Access to Specialists: In addition to the oncology treatment team, our patients have access to social workers who can assist them with educational and practical needs. Those interested in fertility preservation can receive care through the internationally renowned Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine of Weill Cornell Medical College.
- Clinical Trials: Patients may have opportunities to participate in clinical trials of innovative therapies designed just for adolescents and young adults with lymphoma.
- Studying Lymphoma Biology: Our investigators are studying the biology of lymphoma in adolescents and young adults to learn what differentiates lymphoma in patients aged 18 to 30 from the disease in younger and older patients. Working in collaboration with Weill Cornell's Institute for Precision Medicine, the researchers are performing genetic analyses to tease out the biology of the disease — yielding information, which can help guide treatment. The results of these studies may result in more effective lymphoma therapies with fewer side effects.